Abstract
In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab®) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
Original language | English |
---|---|
Pages (from-to) | 198-203 |
Number of pages | 6 |
Journal | Leukemia Research |
Volume | 38 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2014 |
Keywords
- Alemtuzumab
- Biology
- Chronic lymphocytic leukemia
- CLL
- Fludarabine
- Young
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
- Medicine(all)